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Abstract
Hypercalciuria is a major cause of nephrolithiasis, and is a common and complex disorder involving genetic and
environmental factors. Identification of genetic factors for monogenic forms of hypercalciuria is hampered by the limited
availability of large families, and to facilitate such studies, we screened for hypercalciuria in mice from an N-ethyl-N-
nitrosourea mutagenesis programme. We identified a mouse with autosomal dominant hypercalciuria (HCALC1). Linkage
studies mapped the Hcalc1 locus to a 11.94 Mb region on chromosome 6 containing the transient receptor potential cation
channel, subfamily V, members 5 (Trpv5) and 6 (Trpv6) genes. DNA sequence analysis of coding regions, intron-exon
boundaries and promoters of Trpv5 and Trpv6 identified a novel T to C transition in codon 682 of TRPV5, mutating a
conserved serine to a proline (S682P). Compared to wild-type littermates, heterozygous (Trpv5682P/+) and homozygous
(Trpv5682P/682P) mutant mice had hypercalciuria, polyuria, hyperphosphaturia and a more acidic urine, and ,10% of males
developed tubulointerstitial nephritis. Trpv5682P/682P mice also had normal plasma parathyroid hormone but increased 1,25-
dihydroxyvitamin D3 concentrations without increased bone resorption, consistent with a renal defect for the hypercalciuria.
Expression of the S682P mutation in human embryonic kidney cells revealed that TRPV5-S682P-expressing cells had a lower
baseline intracellular calcium concentration than wild-type TRPV5-expressing cells, suggesting an altered calcium
permeability. Immunohistological studies revealed a selective decrease in TRPV5-expression from the renal distal
convoluted tubules of Trpv5682P/+ and Trpv5682P/682P mice consistent with a trafficking defect. In addition, Trpv5682P/682P mice
had a reduction in renal expression of the intracellular calcium-binding protein, calbindin-D28K, consistent with a specific
defect in TRPV5-mediated renal calcium reabsorption. Thus, our findings indicate that the TRPV5 S682P mutant is
functionally significant and study of HCALC1, a novel model for autosomal dominant hypercalciuria, may help further our
understanding of renal calcium reabsorption and hypercalciuria.
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Introduction
Kidney stone disease (nephrolithiasis) affects 12% of men and
5% of women by the seventh decade of life and has a recurrence
rate of ,10% per annum [1]. Approximately 80% of kidney
stones contain calcium as calcium oxalate and/or calcium
phosphate, and hypercalciuria is the most common metabolic
abnormality found in such calcium stone formers [1,2]. The
aetiology of hypercalciuria may involve absorptive, renal, or
resorptive mechanisms, depending on the site of the primary
defect, resulting in intestinal hyperabsorption, impaired renal
tubular reabsorption, or increased bone resorption, respectively
[3]. In addition, hypercalciuria and nephrolithiasis may have a
genetic aetiology, as 35–65% of patients with hypercalciuric
nephrolithiasis have affected family members [2]. Moreover, twin
studies have estimated the heritability of nephrolithiasis and
hypercalciuria as 56% [4] and 52%, [5] respectively, and both
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may occur as polygenic quantitative traits, or as monogenic traits
inherited as autosomal dominant, autosomal recessive or X-linked
disorders [2,6], a situation that is similar to that for many common
clinical disorders, e.g. hypertension and diabetes mellitus [7,8].
However, it is important to note that the polygenic forms of these
diseases including hypercalciuric nephrolithiasis are more com-
mon, whereas the familial monogenic forms are rare [9], and that
the study of both forms has yielded important and novel insights of
homeostatic mechanisms and their roles in disease processes. This
is well illustrated by studies of the different forms of hypercalciuric
nephrolithiasis. Thus, genome-wide association studies, aiming to
reveal gene variants contributing to polygenic traits,in Icelandic
and Dutch populations identified susceptibility risk variants in the
claudin 14 (CLDN14) gene for hypercalciuric nephrolithiasis, [10]
and a study of Swiss renal calcium stone formers has reported an
association between an ancestral haplotype defined by the non-
synonymous polymorphisms of the transient receptor potential
cation channel, subfamily V, member 6 (TRPV6), which resulted
in a gain-of-function and absorptive hypercalciuria [11]. In
addition, studies of monogenic (i.e. familial) forms of hypercalciu-
ric nephrolithiasis have identified: an association between the
human soluble adenylyl cyclase and an autosomal dominant form
of absorptive hypercalciuria [12,13]; gain-of-function mutations of
the calcium-sensing receptor in autosomal dominant hypocalcae-
mia with hypercalciuria [2,14]; mutations of the sodium-
phosphate co-transporter solute family 34 member 3 (SLC34A3),
in an autosomal recessive form of hypophosphataemic rickets with
hypercalciuria [2,15]; mutations of the chloride/proton antiporter,
CLC-5, in Dent’s disease, an X-linked recessive form of
hypercalciuric nephrolithiasis [16]; and mutations of the bumet-
anide-sensitive sodium-potassium-chloride cotransporter
(NKCC2), the renal outer-medullary potassium channel (ROMK),
and the voltage-gated chloride channel, CLC-Kb in autosomal
recessive forms of Bartter’s syndrome type I-III, respectively,
which are associated with hypercalciuria [15]. These latter studies
have been successful as large families with the disorder were
available. However, such families with monogenic forms of
hypercalciuric nephrolithiasis are frequently unavailable, as this
form of the disorder is rare and because hypercalciuric nephro-
lithiasis is a late-onset disorder, and therefore at the time of
presentation of a kidney stone the parents of a proband may be
deceased and younger family members may not have developed
any manifestations of the disorder [17]. To overcome these
difficulties and facilitate the identification of genetic abnormalities
causing hypercalciuric nephrolithiasis, we embarked on studies to
establish mouse models generated using N-ethyl-N-nitrosourea
(ENU), a chemical mutagen that causes point mutations by
alkylation of nucleic acids leading to mispairing and subsequent
single base substitutions during DNA replication [18]. ENU mouse
mutants, which can be associated with loss-of-function, hypomor-
phic, hypermorphic or dominant-negative effects [18], have been
successfully derived for metabolic and renal disorders including a
mouse model with obesity and hyperinsulinaemia caused by a
V145E substitution in the leptin gene [19], and a mouse model for
renal failure due to a C277S substitution in aquaporin-11 [20]. We
now report the identification of an ENU-induced mouse mutant
model for autosomal dominant hypercalciuria, HCALC1, due to
mutation of the transient receptor potential cation channel,
subfamily V, member 5 (Trpv5) gene.
Results
Identification of HCALC1 mice and Trpv5 mutation
The HCALC1 founder mouse was identified from plasma and
urinary biochemical analysis of F1 male offspring of ENU-
mutagenised C57BL/6J male mice and wild-type C3H/HeH
(C3H) female mice. The founder mouse, who was normocalcae-
mic, was found to have a urine calcium/creatinine ratio .10 SD
above the mean of age-matched control males (2.49 vs. 0.2660.20,
respectively at age 16 weeks, 3.93 vs. 0.2860.21, respectively at
age 24 weeks), consistent with idiopathic hypercalciuria [21]._EN-
REF_17 The HCALC1 founder male was mated with normal
C3H females and plasma and urinary analysis of the second-
generation (G2) progeny revealed 10 of 23 offspring were
normocalcaemic but had urine calcium/creatinine ratios .2 to
9-fold above the mean of age-matched control littermates. The
occurrence of hypercalciuria in 43% of the progeny is consistent
with an autosomal dominant phenotype (Figure 1A). The presence
of hypercalciuria in the HCALC1 mice was not associated with
nephrocalcinosis, as renal histology using von Kossa staining to
detect calcium deposits, revealed that the frequency of interstitial
renal cortical calcification (one or more calcified foci/renal cross-
section) in HCALC1 and wild-type (unaffected) mice was similar
(26% and 24%, respectively).
A genome-wide search using chromosome-specific single
nucleotide polymorphisms (SNPs), at 20–30 cM intervals and
DNA from 13 mice (10 hypercalciuric mice and 3 normocalciuric
littermates) revealed co-segregation of the Hcalc1 locus with
chromosome 6 (LOD score = 3.91, 0% recombination). Analysis
using additional chromosome 6 SNPs in 89 G2 mice (39
hypercalciuric and 50 normocalciuric) demonstrated co-segrega-
tion of the Hcalc1 locus with chromosome 6B1/B2, with a peak
LOD score = 26.8 at 0% recombination (Figure 1B). An analysis
of the recombinants observed in the hypercalciuric mice revealed a
17.38 Mb interval flanked by rs13478688 and rs30110406, and
additional analysis including the normocalciuric mice indicated
the critical interval containing the Hcalc1 locus was between
rs13478709 and rs30110406, which is 11.94 Mb in size and
contains 176 genes, including those for Trpv5 and Trpv6.
Sequence analysis of the coding regions, intron-exon boundaries
and promoter sequences of Trpv5 and Trpv6 [22,23] using DNA
from a hypercalciuric G2 mouse and wild-type C57BL/6J and
C3H mice, did not identify a mutation in Trpv6. However, a
heterozygous T to C transition in codon 682 of Trpv5, predicted to
alter a wild-type serine (S) to a mutant proline (P), was identified in
the hypercalciuric mouse (Figure 1C), resulting in gain of a BsaJI
restriction enzyme site, which was used to confirm the heterozy-
gous mutation in all hypercalciuric mice, consistent with an
autosomal dominant trait. The S682P mutation was absent in all
normocalciuric mice (Figure 1C). The S682 residue, located in the
cytoplasmic C-terminus of TRPV5, is evolutionarily conserved in
the TRPV5 sequences of six species and also in TRPV6
(Figure 1D). Thus, the substitution of the polar serine residue for
the nonpolar proline is likely to be a significant mutation and its
effects on channel function were investigated.
In vitro effects of TRPV5 mutation in HCALC1 mice
TRPV5 is an epithelial calcium channel which functions as a
tetramer, is predominantly expressed in the renal distal convoluted
tubule (DCT) and connecting tubule (CNT), and is involved in
vitamin D-regulated renal calcium reabsorption [24,25]. The
effect of the mutation on TRPV5 channel characteristics was
investigated by electrophysiological recordings in Xenopus oocytes
(Figure 2A–D). These revealed no differences between wild-type
TRPV5 and Dominant Hypercalciuria
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and TRPV5-S682P channel properties, thereby indicating that
either the S682P alteration was not a pathogenic mutation or that
the S682P mutation may be having an effect through different
mechanisms, such as impaired trafficking of the channel to the
plasma membrane, which may not be detected in Xenopus
oocytes; either because the ion channel protein is overexpressed in
the heterologous expression system, or because the cellular
machinery that regulates channel trafficking in Xenopus oocytes
may differ from that of mammalian cells. We therefore assessed
the effect of the mutation on TRPV5 channel characteristics in
Human Embryonic Kidney (HEK)-293 cells. Similarly, to the
Xenopus oocyte measurements, whole-cell patch clamp recordings
in HEK293 cells did not reveal differences in current density
carried by Na+ or Ca2+ between TRPV5-WT and TRPV5-S682P
(Figure S1A–D). In addition, Ca2+ dependent inhibition of
Na+currents was similar between TRPV5-WT and TRPV5-
S682P (Figure S1E and F). The absence of any effect by the
mutant may again be due to overexpression of ion channel
proteins in the heterologous system. Moreover, it is important to
note that the whole-cell patch clamp technique results in a dilution
of the intracellular environment, and that this may reduce the
effects of intracellular factors, which may be involved in channel
trafficking. We therefore carried out further studies of the
intracellular effects of the S682P mutation on calcium flux, using
the calcium-responsive dye, Fura-2, as follows. HEK293 cells were
transiently transfected with constructs encoding enhanced green
fluorescent protein (EGFP)-tagged wild-type mouse TRPV5
(TRPV5-wt), mouse TRPV5 with the S682P mutation (TRPV5-
Figure 1. Hypercalciuria in HCALC1 ENU mutant mice and identification of a Trpv5mutation. (A) Urine calcium/creatinine ratios in 23 G2
offspring of the HCALC1 founder male revealed that 10 of the 23 mice were hypercalciuric, consistent with an autosomal dominant inheritance. Bar,
mean calcium/creatinine values. (B) Haplotype analysis of 89 G2 mice (39 hypercalciuric and 50 normocalciuric) was initially undertaken separately in
the hypercalciuric and normocalciuric mice, as the penetrance of HCALC1 was unknown. Haplotype analysis of the hypercalciuric mice localised
Hcalc1 to a 17.38 Mb interval on chromosome 6, flanked by rs13478688 and rs30110406 (broken double-headed arrow). Haplotype analysis using
combined data for the hypercalciuric and normocalciuric mice identified the smaller interval, 11.94-Mb, flanked by rs13478709 and rs30110406 (solid
double-headed arrow). The Hcalc1 locus is inherited with the C57BL/6J haplotype from the F1 founder male. Filled box, C57BL/6J allele; and open
box, C3H/HeH allele. Number of mice observed for each haplotype is shown beneath each column. (C) DNA sequence analysis of Trpv5 identified a
heterozygous T to C transition in codon 682 in hypercalciuric mice predicted to alter a wild-type serine (Ser) to a mutant proline (Pro). This mutation
resulted in gain of a BsaJI restriction enzyme site that was used to confirm the presence of the mutation in the 39 hypercalciuric mice (n = 3 shown)
and its absence in the 50 normocalciuric mice (n = 3 shown). wt, wild-type; m, mutant. (D) Amino acid sequence alignment revealed evolutionary
conservation of the wild-type mouse TRPV5 serine (S) residue at codon 682 (arrowed) in 5 species, as well as in mouse TRPV6 (mTrpv6). Identical
residues are shaded black and conservative changes are shaded grey.
doi:10.1371/journal.pone.0055412.g001
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S682P), or empty (mock) EGFP vector. EGFP positive cells were
monitored for changes in intracellular calcium ([Ca2+]i) in
response to extracellular calcium ([Ca2+]o) changes using the
Ca2+-sensing dye, Fura-2 (Figure 2E). Transient expression of
TRPV5-wt resulted in an elevated basal [Ca2+]i level compared to
mock-transfected cells, due to increased calcium permeability of
the cell. When the cells were superfused with calcium-free
medium, [Ca2+]i in TRPV5-expressing cells decreased to levels
similar to mock-transfected cells. Re-application of 1.4 mM Ca2+
solution induced a rapid increase of [Ca2+]i followed by a gradual
decrease back to basal levels (Figure 2E). No significant changes in
[Ca2+]i were observed in mock-transfected cells in response to
Ca2+ depletion and Ca2+ re-application (Figure 2F). By compar-
ison, cells transfected with TRPV5-S682P showed a lower basal
[Ca2+]i than TRPV5-wt-transfected cells (N=24/group,
p,0.001, Figure 2E–F). The TRPV5-S682P-transfected cells
had a similar response in [Ca2+]i to Ca
2+ depletion and Ca2+ re-
application as that observed in TRPV5-wt-transfected cells. These
data suggest that the S682P mutation in TRPV5 affects baseline
calcium permeability of the channel rather than calcium-induced
channel inactivation, a feature consistent with the hypercalciuric
phenotype observed in HCALC1 mice (Figure 1A). Renal
excretion and histology were therefore further investigated in the
HCALC1 mice.
In vivo effects of TRPV5 mutation in HCALC1 mice
HCALC1 mice were interbred to generate wild-type (Trpv5+/+),
heterozygous (Trpv5682P/+) and homozygous mutant (Trpv5682P/682P)
mice. Trpv5682P/682P mice, were found to be viable, fertile and
morphologically indistinguishable from their Trpv5+/+ and Trpv5682P/+
littermates. Mice between 12–20 weeks of age were housed in
metabolic cages for 24 hours and urine samples collected for
biochemical analysis [26]. Trpv5682P/682P mice were polydypsic and
polyuric compared to Trpv5+/+ mice (p,0.02, Table 1). In addition
Trpv5682P/+ and Trpv5682P/682P mice were hypercalciuric, hyperpho-
sphaturic, and had an acidic urine (p,0.02, Table 1). Plasma calcium
andphosphate concentrationswere similar inTrpv5+/+ andTrpv5682P/+
mice, but Trpv5682P/682P male and female mice had significantly
lower plasma calcium concentrations (p,0.02), whereas only the
Trpv5682P/682P female mice were hypophosphataemic (p,0.02,
Table 1). The lower plasma calcium concentrations in the
Trpv5682P/682P mice were not observed to be associated with
symptoms of neuromuscular irritability or seizures, presumably
because they had mild hypocalcaemia. Indeed, plasma PTH
concentrations in the Trpv5+/+, Trpv5682P/+ and Trpv5682P/682P
mice were not significantly different (Table 1), but the plasma
1,25-dihydroxyvitamin D3 concentrations were significantly
elevated in male and female Trpv5682P/682P mice (p,0.05 and
p,0.02, respectively) (Table 1). The elevated circulating 1,25-
dihydroxyvitamin D3 concentrations observed in the Trpv5
682P/
682P mice indicate that the mild asymptomatic hypocalcaemia,
despite the severe renal loss of calcium in these mutant mice, is
being maintained via a compensatory, 1,25-dihydroxyvitamin
D3 mediated increase in intestinal calcium absorption, as
reported in Trpv5-/- mice [25].
Despite the frequency of interstitial renal cortical calcification
being similar in the HCALC1 and Trpv5+/+ mice, ,10% of
Trpv5682P/+and Trpv5682P/682P male mice had unilateral or
bilateral smaller kidneys (Figure S2) associated with scarring,
whereas 0% of Trpv5+/+ males had such abnormalities. Histolog-
ical examination revealed the presence of interstitial renal fibrosis,
associated with inflammatory cell infiltrates, tubular dilatation,
flattening of tubular epithelia and the presence of numerous cells
and/or cell debris within the dilated lumen of some cortical
tubules in kidneys of ,10% of Trpv5682P/+and Trpv5682P/682P male
mice (Figure 3A). Immunohistochemical staining with antibodies
against CD3, part of the T-cell receptor complex, confirmed an
infiltration of T-cells within the interstitial regions of the renal
cortex of affected kidneys from the Trpv5682P/+and Trpv5682P/682P
male mice, which was absent in Trpv5+/+ kidneys (Figure 3B). In
addition, TUNEL-staining showed apoptosis of renal tubular cells
in the Trpv5682P/+and Trpv5682P/682P male mice, not observed in
Trpv5+/+ kidneys (Figure 3C). These features are consistent with
tubulointerstitial nephritis [27,28].
Hypercalciuria may be associated with increased bone resorp-
tion leading to lower bone mineral density (BMD) and osteopo-
rosis. We therefore assessed for bone abnormalities in the
HCALC1 mice using dual-energy X-ray absorptiometry (DEXA),
micro-computed tomography (microCT) scanning and histology.
DEXA analysis of the femurs of 19–22 week-old Trpv5+/+,
Trpv5682P/+and Trpv5682P/682P mice (n = 8–22/group) did not
reveal any significant differences (in g/cm2: 0.07560.001,
0.07560.001, and 0.07160.002 for Trpv5+/+, Trpv5682P/+and
Trpv5682P/682P female mice, respectively; 0.07160.001,
0.07060.001, and 0.06660.002 for Trpv5+/+, Trpv5682P/+and
Trpv5682P/682P male mice, respectively) In addition, histological
analysis of the femora from males and females did not reveal any
morphological abnormalities in the Trpv5682P/+ or Trpv5682P/682P
mice when compared to Trpv5+/+ mice (Figure S3). Furthermore,
microCT scanning did not reveal any of the major abnormalities
associated with osteoporosis, such as a reduction in trabecular
bone volume [29], in the Trpv5682P/+ and Trpv5682P/682P mice
when compared to Trpv5+/+ mice (Table S1); however, female
Trpv5682P/682P mice were found to have a significantly elevated
bone surface/volume ratio and reduced trabecular thickness which
may be consistent with a deterioration in the microarchitecture of
the bone.
Effects of TRPV5-S682P mutation on TRPV5 and
Calbindin-D28K renal expression
The effects of the S682P mutation on TRPV5 renal expression,
were assessed using kidney cryosections from Trpv5+/+, Trpv5682P/+
and Trpv5682P/682P mice and anti-TRPV5 antibodies. Co-staining
with antibodies against the thiazide-sensitive sodium/chloride co-
transporter (NCC) or aquaporin-2 (AQP2) was performed to
distinguish TRPV5-expression in the DCT and CNT, respective-
ly, as NCC is expressed at the apical regions of DCT cells, with a
decrease in expression towards the most distal part of the DCT
segment, [24]_ENREF_18 whilst AQP2-expression commences at
the CNT and extends throughout the collecting ducts [30,31]. In
Trpv5+/+ mice, TRPV5-immunostaining was observed in the
apical regions of the second half of the DCT (DCT2), and in the
cytoplasmic regions of CNT cells (Figure 3D–E). By contrast, in
Trpv5682P/682P mice, TRPV5-immunofluorescence was reduced,
especially in NCC-positive tubular cells where TRPV5-staining
was absent or appeared diffusely cytoplasmic (Figure 3D–E).
Examination of TRPV5-NCC co-stained sections revealed that in
Trpv5682P/+ kidneys, TRPV5-expression appeared confined to the
DCT2 distal portion where NCC-immunostaining was weakest
(Figure 3D). The number of TRPV5-NCC co-positive cells in the
kidneys of Trpv5682P/+ and Trpv5682P/682P mice were significantly
reduced (p,0.05) in comparison to Trpv5+/+ kidneys (100613%,
5666%, and 2765% for Trpv5+/+, Trpv5682P/+ and Trpv5682P/682P
mice, respectively, n = 5 mice/group, $3 different fields/kidney
section). These differences in protein expression were not due to
differences in transcription, as quantitative PCR analysis demon-
strated that renal Trpv5 mRNA levels in Trpv5+/+, Trpv5682P/+ and
Trpv5682P/682P mice were similar (Figure 4A). Thus, these findings
TRPV5 and Dominant Hypercalciuria
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Figure 2. Channel characteristics of wild-type and mutant TRPV5. (A) Whole-cell currents in TRPV5-WT (V5-WT) and TRPV5-682P (V5-S682P)
injected Xenopus oocytes recorded in response to 300 ms test pulses to various potentials (from 2100 to +60 mV in 10 mV increments). Holding
potential, 0 mV (N=5). (B) Mean current-voltage relationships for TRPV5-WT and TRPV5-682P channels (N = 5). These current-voltage relationships are
similar to those reported for TRPV5 channels [62]. (C) Mean whole-cell tail currents measured in TRPV5-WT and TRPV5-682P injected Xenopus oocytes
during test potentials applied in 10 mV increments from270 to +40 mV after a pre-pulse to2100 mV in TRPV5-WT and TRPV5-682P channels (N = 5).
(D) Time-dependent inhibition of TRPV-WT and TRPV5-682P whole-cell currents. Oocytes were stimulated every 1 s. The peak current amplitude was
normalised to that recorded during the first pulse (N = 4). (E) Representative trace of Fura-2 ratio in HEK293 cells transiently transfected with an empty
EGFP vector (mock), or EGFP-tagged TRPV5-WT or TRPV5-S682P. Cells expressing EGFP were selected and monitored for changes in intracellular Ca2+
levels when extracellular Ca2+ concentrations were varied from 1.4 mM Ca2+ to 0 mM Ca2+ (2 mM EDTA) and 1.4 mM Ca2+ which was facilitated by
superfusion. (F) Fura-2 levels under resting conditions (t0), minimal Fura-2 ratio after EDTA treatment (tmin) and peak level (tmax) upon
administration of 1.4 mM Ca2+ after EDTA treatment. Average data of cells transfected with the empty vector (n = 7), TRPV5-wt (n = 24) and TRPV5-
TRPV5 and Dominant Hypercalciuria
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are consistent with the mutant TRPV5 channel resulting in a
probable intracellular trafficking defect. Interestingly, renal Trpv6-
expression was significantly increased in Trpv5682P/682P mice
compared to Trpv5+/+ mice (Figure 4B), thereby suggesting a
possible compensatory mechanism. Furthermore, expression of
Cyp24a1, which encodes the 1,25-dihydroxyvitamin D3 24-
hydroxylase, the enzyme that inactivates 1,25-dihydroxyvitamin
D3, was significantly decreased in Trpv5
682P/+ and Trpv5682P/682P
mouse kidneys by qPCR (Figure 4C) and Western blot analysis
(Figure 4D, E), consistent with the hypervitaminosis D observed in
Trpv5682P/682P mice (Table 1). Semi-quantitative analysis of
CYP24a1 and TRPV5 protein using whole kidney lysates
confirmed the results obtained by qPCR, and revealed that
CYP24a1 expression was decreased in Trpv5682P/+ and Trpv5682P/
682P mice (Figure 4E), and that TRPV5 expression was similar in
wild-type, Trpv5682P/+ and Trpv5682P/682P mice (data not shown).
Similar semi-quantitative analysis of TRPV6 protein (data not
shown) did not confirm the observed upregulation of mRNA levels
(Figure 4B), although it should be noted that Western blot and
densitometric analysis is less sensitive than quantitative PCR.
Expression of the intracellular vitamin D-regulated calcium-
binding protein calbindin-D28K, which is co-expressed with TRPV5
in the DCT/CNT and is important for facilitating cytosolic calcium
diffusion from the apical to the basolateral part of the epithelial cell,
[32]_ENREF_25 was investigated. Semi-quantitative Western blot
analysis revealed that calbindin-D28K-expression was significantly
decreased in Trpv5682P/682P kidneys but not in Trpv5682P/+ kidneys
(10066%, 125614%, 5263% for Trpv5+/+, Trpv5682P/+ and
Trpv5682P/682P mice, respectively, p,0.02) (Figure 4D, F), an
observation confirmed by immunohistochemical analysis,
(100611%, 109626%, 862% for Trpv5+/+, Trpv5682P/+ and
Trpv5682P/682P mice, respectively, p,0.01) (Figure 4G).
Discussion
Our studies have identified a novel mouse model, HCALC1, for
autosomal dominant hypercalciuria harbouring a S682P mutation
in TRPV5. Importantly, we have provided evidence that this
mutation underlies the observed hypercalciuria as: i) the T to C
substitution in codon 682 of mouse TRPV5 results in substitution
of a highly conserved serine residue, making it unlikely to be a
silent polymorphism (Figure 1); ii) the serine to proline change
results in reduced basal [Ca2+]i level in HEK293 cells expressing
TRPV5-S682P, indicating a defect in the TRPV5-mediated
calcium permeability of the cell (Figure 2); iii) expression of
TRPV5 in Trpv5682P/+ and Trpv5682P/682P kidneys was altered,
particularly in the DCT2 (Figure 3D), consistent with a trafficking
defect of the mutant TRPV5; and iv) renal calbindin-D28K-expres-
sion in Trpv5682P/682P mouse kidneys was reduced, further
supporting a specific defect in TRPV5-mediated calcium reab-
sorption (Figure 4). Moreover, these findings reporting a role for
the TRPV5-S682P mutation in the aetiology of the hypercalciuric
phenotype are in agreement with the observations previously
reported from mice that are null for Trpv5 (Trpv5-/-) [25]. Thus,
inactivation of TRPV5, in these null mice resulted in a decrease in
renal calcium reabsorption, leading to severe urinary calcium loss,
and normocalcaemia was maintained by a compensatory 1,25-
dihydroxyvitamin D3–mediated increase in intestinal calcium
absorption. Furthermore, in the Trpv5-/- mice the increased
plasma 1,25-dihydroxyvitamin D3 concentrations were not asso-
ciated with increased bone resorption because of TRPV5
inactivation in osteoclasts, and this situation is also observed in
the Trpv5682P/+ and Trpv5682P/682P mice (Table 1 and Table S1),
thereby indicating that TRPV5 exerts its effects on extracellular
calcium homeostasis principally by regulating renal calcium
reabsorption. Interestingly, these patterns of calcium handling in
the Trpv5682P/+, Trpv5682P/682P and Trpv5-/- mice, are similar to
those found in many patients with idiopathic hypercalciuria, who
have renal hypercalciuria in association with elevated concentra-
tions of 1,25-dihydroxyvitamin D3, but with normocalcaemia (or
mild hypocalcaemia) and normal (or suppressed) plasma PTH
concentrations [14,21].
TRPV5 is a major protein involved in renal active calcium
reabsorption, although to date, no TRPV5 mutations have been
identified in patients with hypercalciuric kidney stone disease
[33,34]. However, only 29 unrelated patients have been studied,
and this suggests the possibility that TRPV5 mutations may make
a minor contribution and occur in ,3% of patients with
S682P (N= 24) from at least three independent experiments. * p,0.05 for TRPV5-WT or TRPV5-S682P versus cells transfected with empty vector.
# p,0.05 for TRPV5-S682P versus TRPV5-wt transfected cells.
doi:10.1371/journal.pone.0055412.g002
Table 1. Phenotypic characterisation of HCALC1 mice.
Male Female
wt het hom wt het hom
Water intake (ml/24 hr) 3.2260.18 3.9060.24 5.7060.47*¡ 3.7660.16 3.9560.29 6.8060.54*¡
Urine output (ml/24 hr) 1.2260.08 1.5360.14 2.2660.30* 1.6260.08 1.9560.15 3.9760.35*¡
Urine Ca2+/Cr 0.2160.01 1.8560.09* 5.0960.37*¡ 0.2460.01 3.0060.12* 6.5760.40*¡
Urine Phos/Cr 11.760.5 14.460.4* 16.360.5*¡ 10.160.5 12.360.6* 14.460.6*¡
Urine pH 6.9260.07 6.4360.06* 6.1160.05*¡ 6.7560.05 6.1460.07* 5.9460.04*
Plasma calcium (mmol/l) 2.8260.04 2.7460.03 2.6360.03* 2.7760.04 2.8060.04 2.6260.04*¡
Plasma phosphate (mmol/l) 4.7460.18 4.3060.19 4.0760.25 4.1260.23 4.4560.23 3.3160.18*¡
Plasma PTH (pmol/l) 44.366.5 40.365.7 59.668.1 41.664.1 39.365.2 38.763.6
1,25 vitamin D3 (pmol/l) 46.5612.7 77.266.0 181645.9$ 53.666.7 88.3615.4 126.3613.7*
Metabolic cage analysis of Trpv5+/+ (wt), Trpv5682P/+ (het) and Trpv5682P/682P (hom) mice for 24 hours (N = 15–72 mice/group). All data are presented as means6SEM.
$p,0.05 compared to Trpv5+/+, * p,0.02 compared to Trpv5+/+, #p,0.02 compared to Trpv5682P/+ mice, with Bonferroni correction for multiple comparisons.
doi:10.1371/journal.pone.0055412.t001
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hypercalciuric renal stone disease. Indeed, it seems likely that in a
highly heterogenous disorder such as hypercalciuric renal stone
disease, that multiple genes may be involved with each giving rise
to an autosomal inherited disorder and/or making a contribution
to a polygenic trait, which is the likely situation for hypercalciuric
renal stone disease [17]. Moreover, two TRPV5 SNPs, A563T
and L712F, which have been reported to exhibit an increased
calcium influx in Xenopus oocyte assays when compared with the
reference TRPV5 may potentially explain the lower urine calcium
excretion and reduced risk of kidney stones in African-Americans
in whom these SNPs occur more frequently [35]._ENREF_28
This increase in TRPV5 calcium uptake in the A563T variant was
also observed under experimental conditions that mimicked the
compound heterozygous state, or in combination with other
TRPV5 non-synonymous SNP variations [35]._ENREF_28 Our
study, which further establishes the role of TRPV5 in hypercal-
ciuria, indicates that mutational analysis of larger cohorts of
hypercalciuric patients is warranted to assess if TRPV5 mutations
may contribute to 3% (or less), of hypercalciuric renal stone
disease. In addition, the HCALC1 mouse established by this study
provides a pre-clinical model to evaluate treatments (e.g. diet or
drugs) for hypercalciuria as well as facilitating studies of the
physiological role of TRPV5 in renal calcium excretion.
HCALC1 mice are hypercalciuric, hyperphosphaturic, polyuric,
polydypsic and have low urine pH. However, renal calcification in
HCALC1 mice was not different from wild-type despite extreme
calciuresis. These features are similar to the reported phenotype in
Trpv5-/- mice [25]._ENREF_19 It has been postulated that
polyuria and low urine pH reduce the risk of calcium phosphate
precipitation in hypercalciuric mice [25,34]. Studies in Trpv5-/-
mice have shown that increased luminal calcium activates the
apical calcium-sensing receptor in collecting duct cells leading to
AQP2 downregulation and increased activity of the proton pump
H+-ATPase, resulting in polyuria and increased acid secretion into
the urine, respectively [34]._ENREF_29 Abolition of this com-
pensatory urinary acidification in Trpv5-/- mice by genetic ablation
Figure 3. Histological and immunohistochemical assessment of kidneys from HCALC1 mice. Representative images in Trpv5+/+ (wt),
Trpv5682P/+ (het) and Trpv5682P/682P (hom) mice of: (A) Masson’s trichrome staining of renal cortex showing areas of interstitial fibrosis in Trpv5682P/+
and Trpv5682P/682P mice (light blue), (B) anti-CD3-labelling (green) showing a large number of T-lymphocytes present in the interstitial regions of the
Trpv5682P/+ and Trpv5682P/682P mouse kidneys, (C) TUNEL-labelling (green) of the renal cortex showing the presence of tubular cell apoptosis in the
Trpv5682P/+ and Trpv5682P/682P mouse kidneys. Scale bar = 50 mm. (D) Immunohistochemical images of kidney sections from wild-type (wt), Trpv5682P/+
(het) and Trpv5682P/682P (hom) mice, co-stained for TRPV5 (green) and NCC (red). * denotes co-localisation. Scale bar = 50 mm. (E) Kidney sections
from wild-type (wt), Trpv5682P/+ (het) and Trpv5682P/682P (hom) mice, co-stained for TRPV5 (green) and AQP2 (red). * denotes co-localisation. Scale bar
= 50 mm.
doi:10.1371/journal.pone.0055412.g003
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of the H+-ATPase B1 subunit resulted in severe calcium phosphate
precipitation in the renal medulla [34]._ENREF_29 Similar
mechanisms may also contribute to reducing the risk of calcium
precipitation in the presence of hypercalciuria in HCALC1 mice.
The extent of hypercalciuria in Trpv5682P/+ mice (,10-fold above
wild-type) was similar to that reported for Trpv5-/- mice (,6-fold
above wild-type)[25]_ENREF_19, and in Trpv5682P/682P mice, this
was significantly higher than both Trpv5682P/+ and Trpv5-/- (,20-
fold above wild-type), despite TRPV5-S682P causing only an
,40% decrease in basal calcium influx in HEK293 cells (Table 1,
Figure 2E–F). It could be expected that complete loss of TRPV5 in
Trpv5-/- would cause a greater degree of hypercalciuria than the
S682P mutation of TRPV5, which retains some calcium
permeability. However, there was a decrease in TRPV5 protein
expression specifically in the DCT (Figure 4E), suggesting that the
S682P mutation may affect TRPV5 trafficking or regulation, for
example by changing the conformation of the cytoplasmic C-
terminal domain, which contains several protein-binding and
regulatory motifs that regulate the subcellular localisation and
trafficking of TRPV5 [36,37,38,39]. Such a trafficking defect of
mutant TRPV5 would not be detected by the Xenopus oocyte or
HEK293 cells heterologous expression systems (Figure 2 and
Figure S1) as these over-express the ion channel proteins, but may
be detected by immunohistochemistry experiments of the renal
tubules, as these utilise the native expression of proteins and are
therefore more relevant to the physiological state. Indeed, the
results of the immunohistochemistry studies (Figure 3D-3E) are
consistent with the mutant TRPV5-S682P channel resulting in a
trafficking defect, which would not be detected in the Xenopus
oocyte or HEK293 cell heterologous expression systems. A
decrease in apical TRPV5 expression specifically in the DCT in
combination with the lower basal calcium flux of TRPV5-S682P,
would reduce calcium reabsorption in the DCT further. Another
way in which TRPV5 function is regulated is by phosphorylation
of S654, likely by protein kinase C (PKC) as a result of apical
CaSR stimulation which increases calcium flux through TRPV5.
The S682P mutation could be hypothesised to cause a conforma-
tional change in the C-terminus that may render S654 unavailable
to PKC, or may itself cause loss of a phosphorylation site, thus
further decreasing the function of TRPV5-S682P. The further
increase in hypercalciuria in Trpv5682P/682P mice compared to
Trpv5682P/+ mice is likely due to the active TRPV5 channel
consisting of four TRPV5 monomers that form a central pore
[40]_ENREF_34. Thus in Trpv5682P/+ mice, 1 in 16 TRPV5
tetramers will consist of four wild-type TRPV5 monomers, whilst
in Trpv5682P/682P mice, all TRPV5 channels will consist of four
mutant TRPV5 monomers. An assessment of this possibility of a
dominant-negative effect by the mutant TRPV5 was not feasible
by in vitro experiments using the heterologous expression systems
and co-transfection of wild-type and mutant TRPV5 constructs as
the mutation did not affect channel properties when expressed in
the Xenopus oocytes (Figure 2A–D) or HEK293 cells (Figure S1).
Expression of the calbindin-D28K protein was also significantly
reduced in Trpv5682P/682P mice. Such reductions have been
observed in models with defective calcium influx via TRPV5,
such as the Trpv5-/- and Klotho-/- mice [25,41]. This reduction in
calbindin-D28K-expression is likely due to the associated hypervi-
taminosis D in Trpv5682P/682P mice (Table 1) and this finding is
similar to that reported in the Trpv5-/- mice [42]. The elevated
circulating 1,25-dihydroxyvitamin D3 concentrations of the
Trpv5682P/682P mice are the likely result of decreased degradation
as renal Cyp24a1-expression was found to be significantly
decreased (Figure 4E). This observation suggests that cellular
calcium concentration is an important regulator of calbindin-
D28K-expression, overriding the stimulatory effects of vitamin D.
The reduction in calbindin-D28K-expression coupled with the
probable mislocalisation of TRPV5-S682P in DCT tubules could
result in reduced calcium reabsorption, and thus explain the
hypercalciuria observed in Trpv5682P/682P and Trpv5682P/+ mice.
Furthermore, reduction in the interaction between TRPV5 and
calbindin-D28K in cells expressing Trpv5-S628P could explain the
normal channel characteristics observed in TRPV5-S682P chan-
nels (Figure 2), as mutation of calbindin-D28K, leading to loss of
interaction with TRPV5, has previously been demonstrated not to
affect TRPV5 channel characteristics [32]_ENREF_25_ENRE-
F_25_ENREF_25.
Histological analysis of the kidneys of HCALC1 mice demon-
strated an increase in inflammatory infiltrates and tubular damage
in ,10% of male HCALC1 mice, consistent with interstitial
nephritis. We hypothesise that this is a consequence of a
combination of several factors within the HCALC1 mice.
HCALC1 mice are polyuric, resulting in an increased hydrostatic
pressure within tubules that could lead to cell damage. This
cellular damage may lead to increased uric acid release from the
cells [43] and increased inflammatory cell infiltration (Figure 3A–
B). A consequence of cellular damage and the inflammatory
response may be apoptosis of cells as demonstrated by TUNEL
staining within the HCALC1 mouse kidneys (Figure 3C).
Our investigations for bone abnormalities in the Trpv5 mutant
mice did not reveal any significant abnormalities other than a
decrease in trabecular thickness and an increase in the bone
surface/volume in female Trpv5682P/682P mice (Table S1). Our
finding of a decrease in trabecular thickness in the female
Trpv5682P/682P mice is in agreement with the reported observations
in the Trpv5-/- mice [25]. However, male Trpv5-/- mice, unlike
male Trpv5682P/682P mice, also had a decrease in trabecular thick-
ness, and Trpv5-/- male and female mice, unlike Trpv5682P/682P
male and female mice, also had a reduction in cortical bone
thickness [25]. The basis for these differences between the Trpv5-/-
[25] and Trpv5682P/682P mutant mice, may involve at least three
possibilities, which include: differences in the backgrounds of the
strains; the ages at which the mice were investigated; and the
severity of the mutation. Differences in strain background have
been reported to profoundly alter expression of mutant phenotypes
[44], and it is important to note that the Trpv5682P/682P mutant mice
were on a C57BL/6J.C3H background, whereas the Trpv5-/- mice
were on a 129.B6 background [25]; thus it seems likely these
differences in strain background may contribute to the observed
differences in trabecular thickness between the Trpv5682P/682P and
Trpv5-/- males. In addition, the Trpv5682P/682P mice were signifi-
Figure 4. Assessment of Renal Expression of Calcium Regulatory Genes and Proteins. Renal expression of (A) Trpv5, (B) Trpv6 and (C)
Cyp24a1 in wild-type (wt), Trpv5682P/+ (het) and Trpv5682P/682P (hom) mice (n = 6/group) were assessed by quantitative real-time PCR. All data were
normalised to levels of the housekeeping gene Gapdh and wild-type values are expressed as 1. Histogram data are presented as mean 6 SEM.
#p,0.05, $p,0.01, compared to wild-type mice. (D) Western blot analysis of TRPV5, TRPV6, CYP24a1 and calbindin-D28K (CaBP28K) in kidneys of wild-
type (wt), Trpv5682P/+ (het) and Trpv5682P/682P (hom) mice. The a-1 subunit of the Na/K-ATPase and a-tubulin were used as housekeeping genes to
normalize for equal loading. (E) Semi-quantitative densitometry analysis of CYP24a1. (F) Semi-quantitative analysis of CaBP28K. All histogram data are
presented as means 6 SEM. *p,0.05 and **p,0.02 compared to wild-type mice. (G) Immunohistochemical images of calbindin-D28K (CaBP28K)
stained kidney sections from wild-type (wt), Trpv5682P/+ (het) and Trpv5682P/682P (hom) mice. Scale bar = 200 mm.
doi:10.1371/journal.pone.0055412.g004
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cantly older than the Trpv5-/- male mice (19 to 22 weeks versus 8 to
9 weeks of age) [25] at the time of the study; thus the greater
maturity and longer duration of androgen exposure of the
Trpv5682P/682P male mice may have ameliorated any reduction in
trabecular and cortical bone thickness. Finally, it seems likely that
TRPV5-682P represents a less severe mutation than the Trpv5
deletion of the knockout mice, as indicated by the lack of any
significant effect of the TRPV5-682P mutant channel properties
(Figure 2A–2D). The in vivo role of TRPV5 in bone metabolism is
not fully understood and the availability of two mutant mouse
models for TRPV5, with differences in bone phenotypes, will help
such future investigations. TRPV5 is expressed in osteoclasts at the
ruffled border and contributes to bone resorption but it is not
expressed in osteoblasts; in contrast TRPV6 is expressed in both
osteoblasts and osteoclasts but at very low levels, which are,1% of
those in the intestine, and TRPV6 is not involved in osteoblast Ca2+
uptake [31,45,46]. Trpv5-/- mice have been reported to have
increased numbers of osteoclasts, due to stimulation of osteoclast
precursors by the high circulating 1,25(OH)2D concentrations, but
have reduced bone reabsorption due to a lack of TRPV5 activity
[25,46]. However, the basis of the observed in vivo reduction in
cortical bone mass in the Trpv5-/-mice remains to be elucidated and
it has been proposed that TRPV5 may directly regulate osteoclast
differentiation and/or RANKL-induced Ca2+ signaling [47].
Investigation of the Trpv5682P/682P and Trpv5-/- mouse models,
which represent hypomorph and null models, respectively may help
to further elucidate the in vivo roles of TRPV5 in skeletal biology.
In summary, HCALC1 represents the first mouse model
reported to have dominant hypercalciuria due to a missense
mutation in Trpv5. In contrast to the Trpv5-/- model for
hypercalciuria, the presence of TRPV5 with a point mutation in
HCALC1 mice may help elucidate roles for the TRPV5 C-
terminus in the regulation of TRPV5 activity and trafficking, and
the role of TRPV5 in renal mechanisms of calcium homeostasis
and in hypercalciuria.
Methods
Ethics Statement
All animal studies were carried our using guidelines issued by
the Medical Research Council in ‘Responsibility in the Use of
Animals for Medical Research’ (July 1993) and Home Office
Project License Numbers 30/2250 and 30/2752. Experiments
were approved by the Medical Research Council Harwell ethics
committee, and all efforts were made to minimize suffering.
Experimental Animals
Studies were performed in accordance with guidelines issued
under the UK Home Office Project licence. Animals were
maintained in specific pathogen-free facilities, in individual
ventilated cages and a 12-hour light-dark cycle, with free access
to food and water. Mice were fed on Rat and Mouse No. 3 diet
containing 1.15% calcium, 0.82% total phosphorus and 4088.68
units/kg of vitamin D (Special Diets Services, Wytham, Essex,
UK).
Generation of mutant mice
ENU-mutagenesis of C57BL/6J male mice was performed as
previously described [48]._ENREF_37 F1 mice were obtained by
crossing ENU-mutagenised C57BL/6J male mice with C3H/HeH
(C3H) female mice. G2 mice for inheritance testing and mapping
studies were derived by mating the founder male mouse with C3H
female mice, or by in vitro fertilisation of C3H eggs using sperm
from the founder male. Homozygous mutant mice (Trpv5682P/682P)
were generated by intercrossing heterozygous mutant (Trpv5682P/+)
male and female mice.
Phenotype screen
Sixteen-week old F1 male mice were kept in metabolic cages
(Techniplast, Kettering, UK) for 24-hours with free access to food
and water [26]. Mice were weighed before and after, and food and
water intake was monitored. 24-hour urine samples were collected
in the presence of sodium azide and blood samples were collected
from lateral tail vein or the internal jugular vein in lithium heparin
Microvette tubes (Sarstedt, Leicester, UK) following terminal
anaesthesia as previously described [26]. Urine and plasma
chemistry were measured using an Olympus AU400 multi-channel
analyser [26,49]. Urine parameters were calculated as a ratio of
sample creatinine, and plasma calcium was adjusted for plasma
albumin concentration as described previously [26]._ENREF_20
Mice were weighed before and after, and food and water intake
was monitored. 24-hour urine samples were collected in the
presence of sodium azide and blood samples were collected from
lateral tail vein or the internal jugular vein in lithium heparin
Microvette tubes (Sarstedt, Leicester, UK) following terminal
anaesthesia as previously described [26]._ENREF_20 Urine and
plasma chemistry were measured using an Olympus AU400 semi-
automated clinical chemistry analyser [26,49]. Serum parathyroid
hormone (PTH) concentration was measured using an ELISA
specific for mouse intact PTH (Immutopics, San Clemente, CA,
USA) as previously described [50]. Urine parameters were
calculated as a ratio of sample creatinine, and plasma calcium
was adjusted for plasma albumin concentration as described
previously [26]._ENREF_20 Mice with a urine or plasma
parameter that was 2SD above or below the population mean
were retested at 24 weeks of age.
Genetic mapping and DNA Sequence Analysis
DNA was isolated from ear or tail biopsies using the Gentra
PureGene DNA isolation kit (QIAGEN, Crawley, UK). A genome
wide scan was performed on 13 mice by Pyrosequencing on the
PSQ HS 96A Instrument (QIAGEN), using a panel of ,60
informative SNPs, distributed at 20–30cM intervals across 19
autosomes. Further mapping was carried out using more mice and
additional informative SNPs across the candidate interval. The
exons, corresponding intron-exon boundaries and promoters of
mouse Trpv5 and Trpv6 genes [22,23] were PCR-amplified using
gene specific primers (sequences provided on request). DNA
sequences were determined by semi-automated DNA sequencing
and the DNA sequence abnormality confirmed by restriction
enzyme digest of PCR products, using methods previously
described [16],_ENREF_10[51]._ENREF_38_ENREF_40.
Bone Analysis
Dissected formalin-fixed femora from 19–22 week-old Trpv5+/+,
Trpv5682P/+ and Trpv5682P/682P mice (n= 7–22 per group) were
examined by DEXA and microCT. DEXA was carried out using a
PIXImus X-ray densitometer (GE Healthcare, Little Chalfont,
UK). The acquired images were processed using the PIXImus v2.1
software. MicroCT analysis was carried out using a Skyscan
microCT scanner (model 1172a, Skyscan, Belgium) at 50 kV and
200 mA using a 0.5 aluminium filter and a detection pixel size of
4.3 mm2. Images were captured every 0.7u through 180u rotation
of each bone. Scanned images were reconstructed using Skyscan
NRecon software and analysed using the Skyscan CT analysis
software. Trabecular bone was measured over a 1 mm3 volume,
0.2 mm from the growth plate. Trabecular bone volume as
proportion of tissue volume (BV/TV,%), trabecular thickness
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(Tb.Th, mm) and trabecular number (Tb. N, mm-1) were assessed
in this region using the CT analysis software [52]. Histological
analysis was performed using 5 mm sections of femora that were
stained with H&E [49]. Images were collected on a Nikon Eclipse
E400 microscope, equipped with a Nikon DXM1200C digital
camera.
Kidney histology and immunohistochemistry
Dissected kidneys were halved, fixed in 10% neutral-buffered
formalin overnight, and embedded in paraffin wax. Four- mm
sections were prepared and stained with H&E, Masson’s
Trichrome, and von Kossa for the presence of renal calcification
as described previously [49]._ENREF_38 TUNEL-staining for
detection of apoptotic cells was performed using the ApopTag
Fluorescein In Situ Apoptosis Detection kit (Millipore, Watford,
UK) according to the manufacturer’s instructions. The presence of
T-lymphocytes was detected using rabbit anti-CD3 monoclonal
antibodies (ab16669, Abcam, Cambridge, UK), followed by
secondary detection using Alexa Fluor 488-conjugated donkey
anti-rabbit (Molecular Probes, Invitrogen, Paisley, UK). Stained
sections were mounted in mounting medium containing DAPI
(Vector Labs, Peterborough, UK).
For TRPV5 immuno-detection, 8- mm kidney cryosections were
processed for immunofluorescence labelling as previously de-
scribed [53]._ENREF_41 Kidney cryosections were co-stained
with rabbit anti-TRPV5 (ACC-035, Alomone Labs, Jerusalem,
Israel) and goat anti-AQP2 (sc-9882, Santa Cruz, Insight
Biotechnology, Wembley, UK) polyclonal antibodies, or with goat
anti-TRPV5 (sc-23379, Santa Cruz) and rabbit anti-NCC
polyclonal antibodies, followed by the appropriate Alexa Fluor
488- or 594-conjugated secondary antibodies (Molecular Probes).
Images were collected on a Nikon Eclipse E400 microscope,
equipped with a Nikon DXM1200C digital camera. For
comparison of fluorescence intensity, kidney sections stained for
each antibody were photographed under identical exposure
conditions for all mice and NIS-Elements BR 3.0 software used
to count the number of TRPV5-positive and TRPV5-NCC co-
positive cells.
For calbindin-D28K detection, kidneys were fixed in 2% (w/v)
periodate-lysine-paraformaldehyde (PLP), followed by overnight
incubation in 15% (w/v) sucrose. Seven- mm cryosections were
prepared and stained with rabbit anti-calbindin-D28K and images
taken using a 10x objective on a Zeiss fluorescence microscope
(Sliedrecht, The Netherlands) and a Nikon DMX1200 digital
camera. Semi-quantitative determination of calbindin-D28K pro-
tein expression was performed using Image J (image processing
program, NIH, USA), similar to previous publications [54]._EN-
REF_42.
Western blot analysis
For quantification of renal expression, of TRPV5, TRPV6,
CYP24a1 and Calbindin-D28K proteins, mouse total kidney lysates
were prepared and analysed as described previously [55]._EN-
REF_43 Proteins were separated using SDS-PAGE and electro-
transferred to polyvinylidene fluoride membranes (Immobilon-P,
Millipore Corporation, Bedford, MA, USA). Blots were incubated
overnight with rabbit anti-TRPV5, anti-TRPV6, anti-CYP24a1
(all from Santa Cruz, Insight Biotechnology, Wembley, UK), anti-
calbindin-D28K polyclonal antibodies or mouse anti-Na/K-
ATPase a1-subunit monoclonal antibodies (generously provided
by Professor Michael J. Caplan, Yale University School of
Medicine, New Haven, CT, USA). Subsequently, the blots were
incubated with Alexa Fluor 680-conjugated goat anti-rabbit
(Molecular Probes, Invitrogen) and IRDye 800 CW conjugated
goat anti-mouse (LI-COR Biosciences GmbH, Bad Homburg,
Germany) secondary antibodies or with HRP-conjugated goat-
anti-rabbit secondary antibodies (Biorad Laboratories, UK).
Immunoreactive protein was detected using the Odyssey infrared
detection system (Westburg, Leusden, The Netherlands) or
visualized using Pierce ECL Western blotting substrate (Thermo
Fisher Scientific) on a BioRad Chemidoc XRS+ system [56] and
densitometric analysis performed using Image J.
Cell Culture and transfection
Human embryonic kidney (HEK293) cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM, Bio Whittaker
Europe, Vervier, Belgium) containing 10% (v/v) fetal calf serum
(PAA, Linz, Austria), 13 mM NaHCO3, 2 mM L-glutamine, and
0.01 mg/ml ciproxin at 37 uC in a humidity controlled incubator
with 5% CO2. Cells were transiently transfected with the
appropriate plasmids using polyethyleneimine (PEI, Brunswig/
PolySciences Inc) with a DNA:PEI ratio of 6:1. After 24 h,
transfected cells were used for live-cell imaging experiments.
Electrophysiology
Xenopus oocytes were prepared as previously described [57].
Oocytes were injected with ,0.8 ng wild-type or mutant TRPV5
cRNA. The final injection volume was 50nl per oocyte. Isolated
oocytes were used 2 days after injection. For each batch of oocytes,
both wild-type and mutant mRNA were injected, to enable direct
comparison of their effects. Whole-cell currents were recorded
from intact oocytes using the two-electrode voltage-clamp method,
filtered at 1 kHz and digitized at 4 kHz. Oocytes were constantly
perfused at 20–22uC with a solution containing 2.5 mM KCl,
87.5 mM NaCl, 1 mM MgCl2, 1.8 mM CaCl2 and 5 HEPES
(pH 7.4 with KOH). Whole-cell currents were recorded in
response to 400 ms test pulses to various potentials (from –100
to +60 mV in 10 mV increments) from a holding potential of
0 mV. Current versus voltage relationships were constructed by
measuring the current at the end of each pulse and plotting it
against the test pulse potential. Data was plotted using Origin 7
(OriginLab, Northampton, MA, USA).
Recordings in HEK293 cells were performed as described in
detail previously [58]. Briefly, cells were placed in an extracellular
bath solution (150 mM NaCl, 6 mM CsCl, 10 mM glucose,
10 mM HEPES/NaOH, pH 7.4). Currents were determined in
the tight seal whole-cell configuration using a patch clamp
amplifier controlled by Patchmaster software (HEKA, Lambrecht,
Germany). Cells were kept in nominal divalent free solution to
prevent calcium overload. Patch pipettes had resistances between
1 and 4 mV after filling with standard pipette solution (20 mM
CsCl, 100 mM Cs-aspartate, 1 mM MgCl2, 4 mM Na2ATP,
10 mM BAPTA, 10 mM HEPES/CsOH, pH 7.2.). Access
resistances and capacitance were continuously monitored using
the automatic capacitance compensation of the Patchmaster
software. A linear voltage ramp protocol from -100 mV to
+100 mV (within 450 ms) was applied every 2 s from a holding
potential of 20 mV to measure current-voltage (I/V) relations.
Ca2+ currents were measured for 2.5 s at 2100 mV stepping from
a holding potential of +70 mV. Current densities, expressed in
units of membrane capacitance, were calculated from the current
at280 mV during the ramp protocols (by normalizing the current
amplitude to the cell membrane capacitance). All experiments
were performed at room temperature. The analysis and display of
patch clamp data were performed using Igor Pro software
(WaveMetrics, Lake Oswego, USA).
For whole-cell patch clamp measurements, nominal divalent
free solution contained in mM: 150 NaCl, 6 CsCl, 10 Glucose and
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10 HEPES/NaOH, pH 7.4. To measure Na+-current density, 50
mM EDTA was added to the nominal divalent free solution to
chelate divalent cations. 10 mM CaCl2 to the nominal divalent
free solution to measure Ca2+-current density. The standard
intracellular (pipette) solution contained in mM: 100 Cs-aspartate,
20 CsCl, 1 MgCl2, 10 BAPTA, 4 Na2ATP, 10 HEPES/CsOH
pH 7.2. To adjust the intracellular Ca2+ concentration, the
appropriate amount of CaCl2 was added in the presence of
10 mM BAPTA, as determined by the CaBuf program (ftp://ftp.
cc.kuleuven.ac.be/pub/droog-mans/cabuf.zip).
Video imaging of [Ca2+]i using Fura-2-AM
Functional studies were performed using pEGFP vectors
containing full-length wild-type (wt) and mutant (S682P) mouse
Trpv5 cDNA. HEK293 cells were seeded on fibronectin-coated
coverslips (Ø 25 mm) and transfected with the appropriate
pCINeo/IRES-EGFP vector. After 24 hr, cells were loaded with
3 mM Fura-2-AM (Molecular Probes) and 0.01% (v/v) Pluronic F-
129 (Molecular Probes) in DMEM medium at 37uC for 20 min.
After loading, cells were PBS-washed and allowed to equilibrate at
37uC in HEPES-Tris buffer (in mM: 132.0 NaCl, 4.2 KCl, 1.4
CaCl2, 1.0 MgCl2, 5.5 D-glucose and 10 HEPES, titrated to
pH 7.4 with Tris). For Ca2+ free conditions, a similar buffer
composition was used in which Ca2+ was substituted with 2 mM
EDTA. After Fura-2 loading, cells were placed in an incubation
chamber and attached to the stage of an inverted microscope
(Axiovert 200 M, Carl Zeiss, Jena, Germany). Extracellular Ca2+
was changed using a perfusion system and resulting changes in
cytosolic Ca2+ levels were monitored with Fura-2 excited at
340 nm and 380 nm using a monochromator (Polychrome IV,
TILL Photonics, Gra¨felfing, Germany). Fluorescence emission
light was directed by a 415DCLP dichroic mirror (Omega Optical
Inc., Brattleboro, VT, USA) through a 510WB40 emission filter
(Omega Optical Inc.) onto a CoolSNAP HQ monochrome CCD-
camera (Roper Scientific, Vianen, the Netherlands). The integra-
tion time of the CCD-camera was set at 200msec with a sampling
interval of 3 s. All hardware was controlled with Metafluor 6.0
software (Universal Imaging Corporation, Downingtown, PA,
USA). Quantitative image analysis was performed with Meta-
morph 6.0 (Molecular Devices Corporation, Sunnyvale, CA,
USA). For each wavelength, the mean fluorescence intensity was
monitored in an intracellular region and, for purpose of
background correction, an extracellular region of identical size.
After background correction, the fluorescence emission ratio of
340 nm and 380 nm excitation was calculated to determine the
intracellular Ca2+ concentration. All measurements were per-
formed at room temperature. Numerical results were visualized
using Origin Pro 7.5 (OriginLab Corp., Northampton, MA, USA).
Quantitative PCR Analysis
RNA was extracted from whole mouse kidney using Trizol
(Invitrogen Life Technologies) as per manufacturers instructions
[59]. cDNA was prepared from 1 mg of RNA using the Quantitect
Reverse Transcription Kit (Qiagen). qPCR reactions were carried
out using the Rotorgene Sybr Green Kit (Qiagen) in six
independent samples on a Rotorgene 5 (Qiagen) as described
previously [60]. All qPCR test samples were normalized to levels
of the reference gene Gapdh. Threshold cycle (CT) values were
obtained from the start of the log phase on Rotorgene Q Series
Software and CT values analysed in Microsoft Excel 97-2010 using
the Pfaffl method [61]. Data for each gene was normalised to
Gapdh and wild-type values expressed as 1. Data for Trpv5682P/+
and Trpv5682P/682P mice were expressed relative to wild-type mice.
Statistical analysis
Statistical significance between groups was determined by pair-
wise comparisons using a two-tailed unpaired Student’s t-test. For
comparisons of urine and plasma parameters between Trpv5+/+,
Trpv5682P/+ and Trpv5682P/682P mice, Bonferroni’s correction for
multiple comparisons was used.
Supporting Information
Figure S1 Channel characteristics of wild-type and
mutant TRPV5 in HEK293 cells. (A) Whole-cell Na+ currents
in TRPV5-WT and TRPV5-682P transfected HEK293 cells and
(B) their respective mean current-voltage relationships (TRPV5-
WT, n= 7, black; TRPV5-682P, n= 10, red). (C) Whole-cell Ca2+
currents in TRPV5-WT and TRPV5-682P transfected HEK293
cells and (D) their respective mean current-voltage relationships
(TRPV5-WT, n=7, black; TRPV5-682P, n = 10, red). (E) Ca2+-
dependent inactivation is unaltered in the TRPV5-682P mutant.
(F) Whole-cell Na+ currents in TRPV5-WT and TRPV5-682P
transfected HEK293 cells in the presence or absence of 100 nM
Ca2+ in the intracellular solution (n= 5–8 cells) and their
respective mean current-voltage relationships.
(JPG)
Figure S2 Macroscopic findings in kidneys from wild-
type (WT) and TRPV5 mutant male mice. Approximately
10% of Trpv5682P/+ and Trpv5682P/682P male mice had unilateral or
bilateral smaller kidneys. Kidneys from (A) wild-type male mouse
and (B) Trpv5682P/+ mutant male mouse are shown. Trpv5682P/682P
male mice who had smaller kidneys (data not shown) were similar
to those observed in Trpv5682P/+ mice.
(JPG)
Figure S3 Histology of femora from HCALC1 mice.
Representative haematoxylin and eosin (H&E) stained sections from
femora of Trpv5+/+ (wt), Trpv5682P/+ (het) and Trpv5682P/682P (hom)
mice are shown from males and females. Scale bar = 50 mm. The
femora from the Trpv5+/+, Trpv5682P/+ andTrpv5682P/682Pmice were
similar.
(JPG)
Table S1 MicroCT analysis of femora from 19–22 week old
Trpv5+/+, Trpv5682P/+ and Trpv5682P/682P mice.
(DOCX)
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